热门资讯> 正文

Stryker的OptaBlate系统获得FDA批准

2025-05-20 02:04

Stryker (NYSE: NYSE:SYK) announced that its OptaBlate Basivertebral Nerve Ablation system has received clearance from the U.S. Food and Drug Administration.
The OptaBlate system is designed for use in a targeted, minimally invasive procedure that provides long-lasting relief from vertebrogenic pain.

More on Stryker

Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)
Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)
Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript
SA analyst downgrades: PLTR, NEM, USB, SYK, DXCM, BK, ZIM, GERN
Stryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPS

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。